NO20064413L - Multikomponent biologiske transportsystemer - Google Patents
Multikomponent biologiske transportsystemerInfo
- Publication number
- NO20064413L NO20064413L NO20064413A NO20064413A NO20064413L NO 20064413 L NO20064413 L NO 20064413L NO 20064413 A NO20064413 A NO 20064413A NO 20064413 A NO20064413 A NO 20064413A NO 20064413 L NO20064413 L NO 20064413L
- Authority
- NO
- Norway
- Prior art keywords
- compositions
- delivery
- transport systems
- useful
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/793,138 US20040220100A1 (en) | 2000-07-21 | 2004-03-03 | Multi-component biological transport systems |
PCT/US2005/006930 WO2005084361A2 (en) | 2004-03-03 | 2005-03-03 | Multi-component biological transport systems |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064413L true NO20064413L (no) | 2006-12-04 |
Family
ID=34919746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064413A NO20064413L (no) | 2004-03-03 | 2006-09-29 | Multikomponent biologiske transportsystemer |
Country Status (14)
Country | Link |
---|---|
US (2) | US20040220100A1 (ja) |
EP (1) | EP1732584A4 (ja) |
JP (4) | JP2007526330A (ja) |
KR (2) | KR101474880B1 (ja) |
CN (2) | CN102836438A (ja) |
AU (1) | AU2005218606A1 (ja) |
BR (1) | BRPI0508421A (ja) |
CA (1) | CA2558379A1 (ja) |
CR (1) | CR8600A (ja) |
HK (1) | HK1105862A1 (ja) |
IL (1) | IL177814A0 (ja) |
NO (1) | NO20064413L (ja) |
SG (1) | SG150569A1 (ja) |
WO (1) | WO2005084361A2 (ja) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL103558A0 (en) | 1991-10-30 | 1993-03-15 | Schering Corp | Tri-substituted tetrahydrofuran antifungals |
US7563874B2 (en) | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
US20050214327A1 (en) * | 2000-06-02 | 2005-09-29 | Allergan, Inc. | Neurotoxin-containing suppositories and related methods |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
IL154044A0 (en) * | 2000-07-21 | 2003-07-31 | Essentia Biosystems Inc | Multi-component pharmaceutical compositions containing a complex of a positively charged backbone and a negatively charged backbone and methods for the preparation thereof |
US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
US8871224B2 (en) | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
EP1729821B1 (en) * | 2004-03-03 | 2013-07-17 | ReVance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
CA3031270A1 (en) | 2004-03-03 | 2005-12-22 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
DE102004035606A1 (de) * | 2004-07-22 | 2006-03-30 | Biotecon Therapeutics Gmbh | Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit |
US20060073208A1 (en) * | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
FR2879462B1 (fr) * | 2004-12-21 | 2008-12-26 | Sod Conseils Rech Applic | Utilisation de toxine botulique pour une insensibilisation locale prolongee |
US7700738B2 (en) | 2005-01-27 | 2010-04-20 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
RU2007136616A (ru) * | 2005-03-03 | 2009-04-10 | Риванс Терапьютикс, Инк. (Us) | Композиция и способ для местного применения и чрескожного введения ботулинового токсина |
SG160358A1 (en) * | 2005-03-03 | 2010-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
AU2013201374B2 (en) * | 2005-03-03 | 2015-05-21 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US20060222692A1 (en) * | 2005-03-31 | 2006-10-05 | Fairfield Clinical Trials Llc | Method and compositions for transdermal administration of antimicrobial medications |
US20090311767A1 (en) * | 2005-04-21 | 2009-12-17 | Chiles Thomas C | Method for molecular delivery into cells using naonotube spearing |
BRPI0613631A8 (pt) | 2005-07-18 | 2017-12-26 | Univ Massachusetts Lowell | nanoemulsão e método, |
US8518414B2 (en) | 2005-11-17 | 2013-08-27 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
US8318181B2 (en) * | 2005-12-01 | 2012-11-27 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
DK1968648T3 (en) | 2005-12-16 | 2015-07-27 | Amit Shachaf | Diagnostic system for the detection and diagnosis of skin cancer |
US7687650B2 (en) | 2006-02-03 | 2010-03-30 | Jr Chem, Llc | Chemical compositions and methods of making them |
US7927614B2 (en) | 2006-02-03 | 2011-04-19 | Jr Chem, Llc | Anti-aging treatment using copper and zinc compositions |
US7897800B2 (en) | 2006-02-03 | 2011-03-01 | Jr Chem, Llc | Chemical compositions and methods of making them |
CN101074935B (zh) * | 2006-05-19 | 2011-03-23 | 清华大学 | 探测器阵列及设备 |
US7867522B2 (en) | 2006-09-28 | 2011-01-11 | Jr Chem, Llc | Method of wound/burn healing using copper-zinc compositions |
KR101518077B1 (ko) | 2006-12-01 | 2015-05-28 | 안테리오스, 인코퍼레이티드 | 펩티드 나노입자 및 이의 용도 |
CN101848702B (zh) | 2006-12-01 | 2013-07-17 | 安特里奥公司 | 两亲实体纳米粒子 |
CN101583274A (zh) * | 2006-12-29 | 2009-11-18 | 雷文斯治疗公司 | 使用反向序列hiv-tat多肽的运输分子 |
AU2007340162B2 (en) * | 2006-12-29 | 2013-08-01 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT |
CA2680741A1 (en) | 2007-03-22 | 2009-01-15 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
ES2660906T3 (es) | 2007-05-31 | 2018-03-26 | Anterios, Inc. | Nanopartículas de ácido nucleico y usos de las mismas |
CA2694046C (en) * | 2007-07-26 | 2023-09-12 | Revance Therapeutics, Inc. | Cationic peptides and compositions thereof |
WO2009038770A2 (en) * | 2007-09-20 | 2009-03-26 | University Of Massachusetts Cvip | Detoxified recombinant botulinum neurotoxin |
US8273791B2 (en) | 2008-01-04 | 2012-09-25 | Jr Chem, Llc | Compositions, kits and regimens for the treatment of skin, especially décolletage |
ES2524312T3 (es) | 2008-03-14 | 2014-12-05 | Allergan, Inc. | Ensayos de actividad de serotipo A de toxina botulínica de base inmunológica |
US9000131B2 (en) | 2008-07-31 | 2015-04-07 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
CN101671388B (zh) * | 2008-09-09 | 2013-01-02 | 曹国栋 | 血脑屏障穿透性促红细胞生成素及其应用 |
CN102300584A (zh) * | 2008-12-31 | 2011-12-28 | 雷文斯治疗公司 | 可注射的肉毒杆菌毒素制剂 |
RU2011125776A (ru) * | 2008-12-31 | 2013-02-10 | Реванс Терапьютикс, Инк. | Композиции и способы лечения гиперпигментации |
WO2010085753A1 (en) | 2009-01-23 | 2010-07-29 | Jr Chem, Llc | Rosacea treatments and kits for performing them |
PT2413947T (pt) | 2009-04-01 | 2020-05-28 | Revance Therapeutics Inc | Métodos e composições para tratar condições de pele associadas à hiper-reatividade vascular |
MX366344B (es) | 2009-06-25 | 2019-07-05 | Revance Therapeutics Inc | Formulaciones de toxina botulinica libres de albumina. |
PT2490986T (pt) * | 2009-10-21 | 2018-11-13 | Revance Therapeutics Inc | Métodos e sistemas para purificar neurotoxina botulínica não complexada |
US9243057B2 (en) | 2010-08-31 | 2016-01-26 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
US8952057B2 (en) | 2011-01-11 | 2015-02-10 | Jr Chem, Llc | Compositions for anorectal use and methods for treating anorectal disorders |
US20120189677A1 (en) * | 2011-01-20 | 2012-07-26 | Stephen Tonge | Formulations |
US9623117B2 (en) * | 2011-04-04 | 2017-04-18 | Wisconsin Alumni Research Foundation | Method for selective targeting and entry of bacterial toxins to cells |
US20130123647A1 (en) | 2011-05-03 | 2013-05-16 | The Research Foundation Of State University Of New York | Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections |
CA2889833A1 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
US20140242110A1 (en) * | 2013-02-28 | 2014-08-28 | Dt Scimed, Llc | Dose, localization, and formulation of botulinum toxins in skin and muscle |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
FR3030524B1 (fr) * | 2014-12-17 | 2017-01-20 | Hydro-Fill | Utilisation de pll pour ameliorer la stabilite de molecules en solution |
KR102646833B1 (ko) * | 2015-02-27 | 2024-03-13 | 각코호우징 조쇼 가쿠엔 | 막투과성 펩티드를 측쇄에 가지는 고분자 화합물 |
KR101666934B1 (ko) * | 2015-03-05 | 2016-10-17 | 한국유니온제약 주식회사 | 개량형 TAT 펩타이드가 융합된 EGF, 티모신β4, hGH 단백질의 생산방법 및 이들 단백질을 포함하는 화장료 조성물 |
KR101993844B1 (ko) * | 2016-07-20 | 2019-06-27 | 한국유니온제약 주식회사 | 개량형 TAT 펩타이드가 융합된 EGF 또는 hGH 단백질의 생산방법 및 이들 단백질을 포함하는 화장료 조성물 |
JP2019535829A (ja) | 2016-11-21 | 2019-12-12 | エイリオン セラピューティクス, インコーポレイテッド | 大型薬剤の経皮送達 |
KR102479847B1 (ko) * | 2020-05-13 | 2022-12-21 | 주식회사 젠센 | 새로운 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물 |
KR102556731B1 (ko) * | 2020-09-29 | 2023-07-21 | 주식회사 젠센 | 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4078060A (en) * | 1976-05-10 | 1978-03-07 | Richardson-Merrell Inc. | Method of inducing an estrogenic response |
US4434228A (en) * | 1982-04-20 | 1984-02-28 | Genex Corporation | Immobilization of biological materials in condensed polyalkyleneimine polymers |
US4816568A (en) * | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
US5252713A (en) * | 1988-09-23 | 1993-10-12 | Neorx Corporation | Polymeric carriers for non-covalent drug conjugation |
US5420105A (en) * | 1988-09-23 | 1995-05-30 | Gustavson; Linda M. | Polymeric carriers for non-covalent drug conjugation |
US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5652122A (en) * | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US5877278A (en) * | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
US5709861A (en) * | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US6986893B2 (en) * | 1993-12-28 | 2006-01-17 | Allergan, Inc. | Method for treating a mucus secretion |
US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
NO180167C (no) * | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
GB9600272D0 (en) * | 1996-01-06 | 1996-03-06 | Univ Nottingham | Polymers |
JP2002502376A (ja) * | 1997-05-21 | 2002-01-22 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | 生物学的膜を横切る輸送を増強するための組成物および方法 |
US5985434A (en) * | 1997-11-25 | 1999-11-16 | Kimberly-Clark Worldwide, Inc. | Absorbent foam |
US6221355B1 (en) * | 1997-12-10 | 2001-04-24 | Washington University | Anti-pathogen system and methods of use thereof |
WO1999042091A2 (en) * | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
US6261679B1 (en) * | 1998-05-22 | 2001-07-17 | Kimberly-Clark Worldwide, Inc. | Fibrous absorbent material and methods of making the same |
BR9912070A (pt) * | 1998-07-13 | 2001-04-10 | Expression Genetics Inc | Análogo de poliéster de poli-l-lisina como um solúvel, veìculo de distribuição de gene biodegradável |
EP1098642B1 (en) * | 1998-07-27 | 2007-04-04 | Johns Hopkins University | Diamino-propanol-compounds for treating ischemia |
US6280937B1 (en) * | 1998-08-14 | 2001-08-28 | Rigel Pharmaceuticals, Inc. | Shuttle vectors |
US6958147B1 (en) * | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
KR20010089347A (ko) * | 1998-10-27 | 2001-10-06 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 상처 치료 증진 방법 |
JP2002532388A (ja) * | 1998-12-02 | 2002-10-02 | イ・デ・エム・イミュノ−デジネ・モレキュル | 生物学的分子を細胞中へ移入させやすくする新規なオリゴマーコンジュゲート |
WO2000034308A2 (en) * | 1998-12-10 | 2000-06-15 | Washington University | Protein transduction system and methods of use thereof |
US6627632B2 (en) * | 1998-12-14 | 2003-09-30 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
US7056656B1 (en) * | 1999-01-25 | 2006-06-06 | University Of Medicine And Dentistry Of New Jersey | Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA |
US20030236214A1 (en) * | 1999-06-09 | 2003-12-25 | Wolff Jon A. | Charge reversal of polyion complexes and treatment of peripheral occlusive disease |
US7008924B1 (en) * | 1999-07-21 | 2006-03-07 | Amgen, Inc. | VGF fusion polypeptides |
EP1210121A2 (en) * | 1999-08-24 | 2002-06-05 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
US7229961B2 (en) * | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US6730293B1 (en) * | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US20030104622A1 (en) * | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
US6458763B1 (en) * | 1999-09-17 | 2002-10-01 | Depuy Orthopeadics | Bone sialoprotein-based compositions for enhancing connective tissue repair |
US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
US6844324B1 (en) * | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
US7070807B2 (en) * | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
US20040109871A1 (en) * | 2000-01-06 | 2004-06-10 | Pascual David W. | M cell directed vaccines |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US20020009491A1 (en) * | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
IL154044A0 (en) * | 2000-07-21 | 2003-07-31 | Essentia Biosystems Inc | Multi-component pharmaceutical compositions containing a complex of a positively charged backbone and a negatively charged backbone and methods for the preparation thereof |
US20030219462A1 (en) * | 2000-07-21 | 2003-11-27 | Allergan Sales, Inc | Clostridial neurotoxin compositions and modified clostridial neurotoxins |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US7491799B2 (en) * | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
US20030215412A1 (en) * | 2000-07-21 | 2003-11-20 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US6696038B1 (en) * | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
US20020127247A1 (en) * | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
US20020086036A1 (en) * | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
US7255865B2 (en) * | 2000-12-05 | 2007-08-14 | Allergan, Inc. | Methods of administering botulinum toxin |
JP2005508832A (ja) * | 2001-02-16 | 2005-04-07 | セルゲイト, インコーポレイテッド | 間隔を開けてアルギニン部分を含むトランスポーター |
CA2367636C (en) * | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
JP2005508990A (ja) * | 2001-11-07 | 2005-04-07 | ファルマシア・コーポレーション | 真核細胞におけるポリアミドの取込みおよび核蓄積を促進する方法 |
US7060498B1 (en) * | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
JP2005538035A (ja) * | 2001-12-11 | 2005-12-15 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | グアニジニウム輸送試薬および結合体 |
US20030113349A1 (en) * | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
JP2005525096A (ja) * | 2002-01-09 | 2005-08-25 | ユニバーシティ オブ ローザンヌ | Jnkシグナル伝達経路の細胞浸透性ペプチドインヒビター |
KR100468316B1 (ko) * | 2002-01-29 | 2005-01-27 | 주식회사 웰진 | Dna의 세포 또는 조직 내 전달 효율을 높이는 펩타이드 |
AU2003216389A1 (en) * | 2002-02-21 | 2003-09-09 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
US7476390B2 (en) * | 2002-02-26 | 2009-01-13 | Maxygen, Inc. | Flavivirus antigens |
CA2476589C (en) * | 2002-02-27 | 2014-02-25 | Pharmain, Ltd. | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
US6688311B2 (en) * | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
US7097841B2 (en) * | 2002-05-10 | 2006-08-29 | New Century Pharmaceuticals, Inc. | Ferritin fusion proteins for use in vaccines and other applications |
US20030215395A1 (en) * | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
US7459164B2 (en) * | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
NZ537120A (en) * | 2002-05-31 | 2008-07-31 | Univ Jefferson | Compositions and methods for transepithelial molecular transport |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
US7071167B2 (en) * | 2002-11-13 | 2006-07-04 | L'oreal | Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines |
US6866856B2 (en) * | 2002-12-31 | 2005-03-15 | Avon Products, Inc. | Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
WO2004084805A2 (en) * | 2003-03-19 | 2004-10-07 | The J. David Gladstone Institutes | Acetylated tat polypeptides and methods of use thereof |
WO2004084839A2 (en) * | 2003-03-24 | 2004-10-07 | Cady Roger K | Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
US20040192754A1 (en) * | 2003-03-24 | 2004-09-30 | Shapira Nathan Andrew | Methods for treating idiopathic hyperhidrosis and associated conditions |
WO2005030119A2 (en) * | 2003-04-11 | 2005-04-07 | Allergan, Inc. | Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
CA3031270A1 (en) * | 2004-03-03 | 2005-12-22 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
EP1729821B1 (en) * | 2004-03-03 | 2013-07-17 | ReVance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US7691381B2 (en) * | 2004-04-15 | 2010-04-06 | Allergan, Inc. | Stabilized biodegradable neurotoxin implants |
US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
AU2005274822B2 (en) * | 2004-07-26 | 2008-10-30 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
RU2007136616A (ru) * | 2005-03-03 | 2009-04-10 | Риванс Терапьютикс, Инк. (Us) | Композиция и способ для местного применения и чрескожного введения ботулинового токсина |
-
2004
- 2004-03-03 US US10/793,138 patent/US20040220100A1/en not_active Abandoned
-
2005
- 2005-03-03 KR KR1020137002594A patent/KR101474880B1/ko active IP Right Grant
- 2005-03-03 CA CA002558379A patent/CA2558379A1/en not_active Abandoned
- 2005-03-03 AU AU2005218606A patent/AU2005218606A1/en not_active Abandoned
- 2005-03-03 JP JP2007501982A patent/JP2007526330A/ja active Pending
- 2005-03-03 KR KR1020067020212A patent/KR20070027526A/ko not_active Application Discontinuation
- 2005-03-03 US US10/591,485 patent/US20080200373A1/en active Granted
- 2005-03-03 CN CN2012102972738A patent/CN102836438A/zh active Pending
- 2005-03-03 CN CN2005800140063A patent/CN1950100B/zh active Active
- 2005-03-03 BR BRPI0508421-0A patent/BRPI0508421A/pt not_active Application Discontinuation
- 2005-03-03 SG SG200901492-9A patent/SG150569A1/en unknown
- 2005-03-03 WO PCT/US2005/006930 patent/WO2005084361A2/en active Application Filing
- 2005-03-03 EP EP05724470A patent/EP1732584A4/en not_active Withdrawn
-
2006
- 2006-08-31 IL IL177814A patent/IL177814A0/en unknown
- 2006-09-07 CR CR8600A patent/CR8600A/es unknown
- 2006-09-29 NO NO20064413A patent/NO20064413L/no not_active Application Discontinuation
-
2007
- 2007-10-16 HK HK07111146.3A patent/HK1105862A1/xx unknown
-
2015
- 2015-01-28 JP JP2015014631A patent/JP2015108005A/ja active Pending
-
2017
- 2017-04-05 JP JP2017075032A patent/JP2017149741A/ja active Pending
- 2017-04-05 JP JP2017075033A patent/JP2017149742A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2005084361A3 (en) | 2006-03-16 |
KR20070027526A (ko) | 2007-03-09 |
IL177814A0 (en) | 2006-12-31 |
US20040220100A1 (en) | 2004-11-04 |
JP2017149741A (ja) | 2017-08-31 |
CN1950100B (zh) | 2012-10-03 |
JP2007526330A (ja) | 2007-09-13 |
JP2017149742A (ja) | 2017-08-31 |
AU2005218606A1 (en) | 2005-09-15 |
KR101474880B1 (ko) | 2014-12-19 |
KR20130027563A (ko) | 2013-03-15 |
BRPI0508421A (pt) | 2007-07-24 |
EP1732584A2 (en) | 2006-12-20 |
CN1950100A (zh) | 2007-04-18 |
CA2558379A1 (en) | 2005-09-15 |
CN102836438A (zh) | 2012-12-26 |
HK1105862A1 (en) | 2008-02-29 |
US20080200373A1 (en) | 2008-08-21 |
CR8600A (es) | 2008-01-21 |
WO2005084361A2 (en) | 2005-09-15 |
JP2015108005A (ja) | 2015-06-11 |
EP1732584A4 (en) | 2009-07-15 |
SG150569A1 (en) | 2009-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064413L (no) | Multikomponent biologiske transportsystemer | |
WO2005120546A3 (en) | Compositions and methods for topical diagnostic and therapeutic transport | |
BRPI0816117B8 (pt) | anticorpo monoclonal isolado ou fragmento do mesmo, composiçãofarmacêutica, kit para tratamento de desordens relacionadas com colesterol, e, uso de uma proteína de ligação de antígeno ou de um anticorpo monoclonal ou fragmento do mesmo | |
CY1118153T1 (el) | Αγωγη μικροβιακων μολυνσεων | |
NO20085131L (no) | Lyofiliserte preparater av anti-EGFR-antistoffer | |
WO2006042149A3 (en) | Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides | |
SG170793A1 (en) | Anti-mn antibodies and methods of using same | |
WO2008134724A3 (en) | Methods for administering anti-il-5 antibodies | |
EA200970880A1 (ru) | Стабильные композиции на основе антител | |
BR0315161A (pt) | Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição | |
WO2011060206A3 (en) | Material and methods for treating or preventing her-3 associated diseases | |
EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
WO2007011606A3 (en) | USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS | |
EA200700136A1 (ru) | Анти-cd154-антитела | |
WO2013025834A3 (en) | Compositions and methods related to antibodies to staphylococcal protein a | |
WO2004076644A3 (en) | A composition for delivering an agent to a target cell and uses thereof | |
WO2007016285A3 (en) | M-csf specific monoclonal antibody and uses thereof | |
DK2054431T3 (da) | Konformere af bakterielle adhæsiner | |
UA107330C2 (uk) | Туберкульозний білок rv3616c та його застосування | |
EA200970694A1 (ru) | ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ | |
EA200801174A1 (ru) | Антитела-миметики glp-2, полипептиды, композиции, способы и применения | |
EA201100071A1 (ru) | Новые композиции и способы | |
WO2010009856A3 (en) | Goodpasture antigen binding protein and its detection | |
AU2018281871A1 (en) | Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins | |
BR112020027063A2 (pt) | Tratamento de dor de cabeça com uso de anticorpos anti-cgrp |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |